Literature DB >> 25031340

Prolidase is required for early trafficking events during influenza A virus entry.

Marie O Pohl1, Thomas O Edinger1, Silke Stertz2.   

Abstract

UNLABELLED: Influenza A virus (IAV) entry is a multistep process that requires the interaction of the virus with numerous host factors. In this study, we demonstrate that prolidase (PEPD) is a cellular factor required by IAV for successful entry into target cells. PEPD was selected as a candidate during an entry screen performed on nonvalidated primary hits from previously published genome-wide small interfering RNA (siRNA) screens. siRNA-mediated depletion of PEPD resulted in the decreased growth of IAV during mono- and multicycle growth. This growth defect was independent of cell type or virus strain. Furthermore, IAV restriction was apparent as early as 3 h postinfection, and experiments in the absence of protein biosynthesis revealed that the nuclear import of viral ribonucleoprotein complexes (vRNPs) was already blocked in the absence of PEPD. These results led us to investigate which step during entry was affected. Receptor expression, IAV attachment, or IAV internalization was not dependent on the presence of PEPD. However, when looking at the distribution of incoming IAV particles in PEPD-knockdown cells, we found a localization pattern that differed from that in control cells: IAV mostly localized to the cell periphery, and consequently, viral particles displayed reduced colocalization with early and late endosome markers and fusion between viral and endosomal membranes was strongly reduced. Finally, experiments using a competitive inhibitor of PEPD catalytic activity suggested that the enzymatic function of the dipeptidase is required for its proviral effect on IAV entry. In sum, this study establishes PEPD as a novel entry factor required for early endosomal trafficking of IAV. IMPORTANCE: Influenza A virus (IAV) continues to be a constant threat to public health. As IAV relies on its host cell for replication, the identification of host factors required by the virus is of importance. First, such studies often reveal novel functions of cellular factors and can extend our knowledge of cellular processes. Second, we can further our understanding of processes that are required for the entry of IAV into target cells. Third, the identification of host factors that contribute to IAV entry will increase the number of potential targets for the development of novel antiviral drugs that are of urgent need. Our study identifies prolidase (PEPD) to be a novel entry factor required by IAV for correct routing within the endosomal compartment following virus internalization. Thereby, we link PEPD, which has been shown to play a role during collagen recycling and growth factor signaling, to early events of viral infection.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25031340      PMCID: PMC4178778          DOI: 10.1128/JVI.00800-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Fusion mutants of the influenza virus hemagglutinin glycoprotein.

Authors:  R S Daniels; J C Downie; A J Hay; M Knossow; J J Skehel; M L Wang; D C Wiley
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

2.  Acidification of macrophage and fibroblast endocytic vesicles in vitro.

Authors:  C J Galloway; G E Dean; M Marsh; G Rudnick; I Mellman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

3.  Clinical and biochemical characteristics of prolidase deficiency in siblings.

Authors:  B J Freij; H L Levy; G Dudin; D Mutasim; M Deeb; V M Der Kaloustian
Journal:  Am J Med Genet       Date:  1984-11

4.  Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes.

Authors:  T Maeda; S Ohnishi
Journal:  FEBS Lett       Date:  1980-12-29       Impact factor: 4.124

5.  Studies on the mechanism of influenza virus entry into cells.

Authors:  S Patterson; J S Oxford; R R Dourmashkin
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

Review 6.  Prolidase function in proline metabolism and its medical and biotechnological applications.

Authors:  R L Kitchener; A M Grunden
Journal:  J Appl Microbiol       Date:  2012-05-10       Impact factor: 3.772

7.  Infectious cell entry mechanism of influenza virus.

Authors:  A Yoshimura; K Kuroda; K Kawasaki; S Yamashina; T Maeda; S Ohnishi
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

8.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

9.  Infectious entry pathway of influenza virus in a canine kidney cell line.

Authors:  K S Matlin; H Reggio; A Helenius; K Simons
Journal:  J Cell Biol       Date:  1981-12       Impact factor: 10.539

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  10 in total

1.  Measuring Attachment and Internalization of Influenza A Virus in A549 Cells by Flow Cytometry.

Authors:  Marie O Pohl; Silke Stertz
Journal:  J Vis Exp       Date:  2015-11-04       Impact factor: 1.355

2.  Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface Expression.

Authors:  Kirk J Lubick; Shelly J Robertson; Kristin L McNally; Brett A Freedman; Angela L Rasmussen; R Travis Taylor; Avram D Walts; Seitaro Tsuruda; Mizuki Sakai; Mariko Ishizuka; Elena F Boer; Erin C Foster; Abhilash I Chiramel; Conrad B Addison; Richard Green; Daniel L Kastner; Michael G Katze; Steven M Holland; Antonella Forlino; Alexandra F Freeman; Manfred Boehm; Kentaro Yoshii; Sonja M Best
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

3.  Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.

Authors:  Joel Oppliger; Giulia Torriani; Antonio Herrador; Stefan Kunz
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

4.  Cathepsin W Is Required for Escape of Influenza A Virus from Late Endosomes.

Authors:  Thomas O Edinger; Marie O Pohl; Emilio Yángüez; Silke Stertz
Journal:  MBio       Date:  2015-06-09       Impact factor: 7.867

5.  Identification of Polo-like kinases as potential novel drug targets for influenza A virus.

Authors:  Marie O Pohl; Jessica von Recum-Knepper; Ariel Rodriguez-Frandsen; Caroline Lanz; Emilio Yángüez; Stephen Soonthornvacharin; Thorsten Wolff; Sumit K Chanda; Silke Stertz
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

Review 6.  Recent strategies and progress in identifying host factors involved in virus replication.

Authors:  Renate König; Silke Stertz
Journal:  Curr Opin Microbiol       Date:  2015-06-23       Impact factor: 7.934

Review 7.  Principles of Virus Uncoating: Cues and the Snooker Ball.

Authors:  Yohei Yamauchi; Urs F Greber
Journal:  Traffic       Date:  2016-03-31       Impact factor: 6.215

8.  Influenza Virus Segment Composition Influences Viral Stability in the Environment.

Authors:  Thomas Labadie; Christophe Batéjat; Jean-Claude Manuguerra; India Leclercq
Journal:  Front Microbiol       Date:  2018-07-09       Impact factor: 5.640

9.  Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target.

Authors:  Emilio Yángüez; Annika Hunziker; Maria Pamela Dobay; Soner Yildiz; Simon Schading; Elizaveta Elshina; Umut Karakus; Peter Gehrig; Jonas Grossmann; Ronald Dijkman; Mirco Schmolke; Silke Stertz
Journal:  Nat Commun       Date:  2018-09-11       Impact factor: 14.919

Review 10.  Functional Genomic Strategies for Elucidating Human-Virus Interactions: Will CRISPR Knockout RNAi and Haploid Cells?

Authors:  Jill M Perreira; Paul Meraner; Abraham L Brass
Journal:  Adv Virus Res       Date:  2016-03-02       Impact factor: 9.937

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.